Increasing Obesity and Diabetes Contribute to Drug Eluting Balloons Market Growth

by Dr. Sunil Shroff on  February 13, 2012 at 6:01 PM Heart Disease News   - G J E 4
Increased levels of obesity and diabetes have caused a sharp rise in the prevalence of Peripheral Vascular Disease (PVD) in recent years and will contribute to the expansion of the Drug Eluting Balloons (DEB) market, business intelligence specialist GlobalData has found.
Increasing Obesity and Diabetes Contribute to Drug Eluting Balloons Market Growth
Increasing Obesity and Diabetes Contribute to Drug Eluting Balloons Market Growth

The new report* suggests that the value of the market is expected to almost double by 2017, reaching a value of $127 million. This will largely be due to an increase in physician uptake as long-term clinical data is released supporting their effectiveness and as the device is adopted for new indications such as PVD. US Food and Drug Administration (FDA) product approvals over the next two to three years are also expected to boost future uptake, playing on the existing importance of the US market and the current unmet need in the interventional cardiology devices market.

Of course, with further budget cuts expected for the healthcare industry in 2012, cost and patient compliance are two additional factors promoting the use of DEBs. Offering improved efficacy and patient safety for some indications, these products have the potential to create a niche market. In fact, preliminary clinical trial results suggest that DEBs could become the standard treatment for PVD and complex lesions in the future.

GlobalData analysts suggest that PVD, Small Vessel Disease (SVD), bifurcated lesions and In-Stent Restenosis (ISR) could represent a $2 billion untapped market. This market is set to be further boosted by the complications associated with long-term antiplatelet therapy. The risks of bleeding and contraindications limit current interventions and further the potential of DEBs in the healthcare industry.

Among the products set to contribute to the growth of the DEB market is B. Braun's product, SeQuent Please, which currently accounts for the highest number of completed and ongoing clinical trials. Bayer's PACCOCATH technology has also demonstrated success in animal models and both these products are expected to receive regulatory approval in the next two to three years.

(Source - GLOBALDATA, Londn, UK)

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All